Tecentriq
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation. The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.
Analyst Outlook
Tecentriq (atezolizumab; Roche/Chugai) is being positioned as a first-line therapy in combination with Avastin (bevacizumab; Genentech/Roche/Chugai) for the treatment of patients with advanced or metastatic renal cell carcinoma (RCC). Competition among therapies targeting the programmed death-1 (PD-1) receptor and its ligand (PD-L1) is expected to be intense with four therapies expected to be available for use in the lucrative first-line setting by the end of the forecast period. In addition to its development for the first-line setting, Tecentriq is expected to be the first PD-1/PD-L1 therapy approved for the adjuvant setting. Following this, competition in this setting is expected from other PD-1/PD-L1 therapies Keytruda (pembrolizumab; Merck & Co) and Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) + Yervoy (ipilimumab; Bristol-Myers Squibb). Bavencio (avelumab; Merck KGaA/Pfizer) is not yet being investigated for use in the adjuvant setting.
CONTENTS
6 OVERVIEW
6 Drug Overview
7 Product Profiles
7 Tecentriq : Renal cell carcinoma (RCC)
18 Tecentriq : Non-small cell lung cancer (NSCLC)
36 Tecentriq : Melanoma
49 Tecentriq : Prostate cancer
59 Tecentriq : Colorectal cancer (CRC)
73 Tecentriq : Ovarian cancer
83 Tecentriq : Bladder cancer
95 atezolizumab : Breast cancer: triple-negative
LIST OF FIGURES
12 Figure 1: Tecentriq for RCC – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tecentriq for RCC
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tecentriq for RCC
16 Figure 4: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
27 Figure 5: Tecentriq for non-small cell lung cancer – SWOT analysis
28 Figure 6: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
29 Figure 7: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
31 Figure 8: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
41 Figure 9: Tecentriq for melanoma – SWOT analysis
42 Figure 10: Datamonitor Healthcare’s drug assessment summary of Tecentriq for melanoma
43 Figure 11: Datamonitor Healthcare’s drug assessment summary of Tecentriq for melanoma
45 Figure 12: Tecentriq sales for melanoma across the US and five major EU markets, by country, 2017–26
52 Figure 13: Tecentriq for prostate cancer – SWOT analysis
53 Figure 14: Datamonitor Healthcare’s drug assessment summary of Tecentriq for prostate cancer
54 Figure 15: Datamonitor Healthcare’s drug assessment summary of Tecentriq for prostate cancer
56 Figure 16: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
64 Figure 17: Tecentriq for colorectal cancer – SWOT analysis
65 Figure 18: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
66 Figure 19: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
68 Figure 20: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
78 Figure 21: Tecentriq for ovarian cancer – SWOT analysis
79 Figure 22: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
80 Figure 23: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
89 Figure 24: Tecentriq for urothelial bladder cancer – SWOT analysis
90 Figure 25: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer
91 Figure 26: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer
100 Figure 27: Atezolizumab for triple-negative breast cancer – SWOT analysis
101 Figure 28: Datamonitor Healthcare’s drug assessment summary of atezolizumab for triple-negative breast cancer
102 Figure 29: Datamonitor Healthcare’s drug assessment summary of atezolizumab for triple-negative breast cancer
LIST OF TABLES
8 Table 1: Tecentriq drug profile
9 Table 2: Tecentriq Phase III data in RCC
11 Table 3: Tecentriq Phase III trials in RCC
17 Table 4: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
18 Table 5: Tecentriq drug profile
20 Table 6: Tecentriq pivotal trial data in non-small cell lung cancer
22 Table 7: Tecentriq late-phase trial data in non-small cell lung cancer
25 Table 8: Tecentriq ongoing late-phase trial data in non-small cell lung cancer
32 Table 9: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
34 Table 10: Tecentriq patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
37 Table 11: Tecentriq drug profile
38 Table 12: Tecentriq ongoing late-phase trials in melanoma
40 Table 13: Tecentriq early-phase data in melanoma
46 Table 14: Tecentriq sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
48 Table 15: Tecentriq patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
49 Table 16: Tecentriq drug profile
51 Table 17: Tecentriq Phase III trials in prostate cancer
57 Table 18: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
59 Table 19: Tecentriq drug profile
61 Table 20: Tecentriq Phase III trial in colorectal cancer
63 Table 21: Tecentriq early-phase data in colorectal cancer
69 Table 22: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
71 Table 23: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
74 Table 24: Tecentriq drug profile
75 Table 25: Tecentriq Phase III trials in ovarian cancer
77 Table 26: Overview of Phase I data for Tecentriq in ovarian cancer
84 Table 27: Tecentriq drug profile
86 Table 28: Tecentriq pivotal trial data in urothelial bladder cancer
87 Table 29: Tecentriq ongoing late-phase trials in urothelial bladder cancer
96 Table 30: Atezolizumab drug profile
97 Table 31: Atezolizumab Phase III trial in triple-negative breast cancer
98 Table 32: Atezolizumab Phase Ib data in triple-negative breast cancer
99 Table 33: Atezolizumab Phase I data in triple-negative breast cancer
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the